scholarly journals The Healing-Promoting Properties of Selected Cyclitols—A Review

Nutrients ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1891 ◽  
Author(s):  
Agnieszka Owczarczyk-Saczonek ◽  
Lesław Lahuta ◽  
Magdalena Ligor ◽  
Waldemar Placek ◽  
Ryszard Górecki ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Signal Transduction ◽  
Polycystic Ovarian Syndrome ◽  
Therapeutic Option ◽  
Hormonal Profile ◽  
Anti Cancer ◽  
Low Toxicity ◽  
Physiological Benefits ◽  
Galactosyl Cyclitols ◽  
Ovarian Syndrome

Introduction: Myo-inositol and its derivatives cyclitols play an important role in the processes of cell regulation, signal transduction, osmoregulation, and ion channel physiology, and are a component of the cell membrane. Free cyclitols present in food or released during the degradation of galactosyl cyclitols by bacteria (in digestive tract) show some physiological benefits. Aim: The aim of this paper is to present and analyze the documented data about curative and healing properties of cyclitols. Results and discussion: Cyclitols are well known compounds in the treatment of an accompanied diabetes insulin resistance, and also obesity and polycystic ovarian syndrome. d-chiro-Inositol deficiency exacerbates insulin resistance in the liver, muscles, and fat, while depletion of myo-inositol results in the development of diabetic complications. Cyclitols are successfully applied in treatment of polycystic ovarian syndrome, simultaneous are observed effective reducing of BMI, improving the hormonal profile, and increasing fertility. Moreover, cyclitols have anti-atherogenic, anti-oxidative, anti-inflammatory, and anti-cancer properties. Conclusion: The properties of cyclitols may be a good therapeutic option in the reduction of metabolically induced inflammation. Due to well drugs tolerance and low toxicity of these compounds, cyclitols are recommend for pregnant women and also for children. Another advantage is their widespread presence and easy availability, which encourages their use in medicine.

The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Vasilios Pergialiotis ◽  
Eftihios Trakakis ◽  
Charalampos Chrelias ◽  
Nikolaos Papantoniou ◽  
Erifili Hatziagelaki
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovarian Syndrome ◽  
Univariate Analysis ◽  
Density Lipoprotein ◽  
The Body ◽  
Human Reproduction ◽  
Model Assessment ◽  
Hormonal Profile ◽  
The Impact ◽  
Ovarian Syndrome

Abstract Background The severity of polycystic ovarian syndrome (PCOS) has been clearly associated with insulin resistance, obesity and metabolic syndrome. The purpose of the present cross-sectional study is to investigate whether mild hypercholesterolemia alters the biochemical and clinical profile of PCOS patients. Methods Our study is based on a prospectively collected population of women of reproductive age who were diagnosed with PCOS according to the definition of the Rotterdam European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ASRM/ESHRE) criteria. For the correlation analysis we used the non-parametric Spearman’s rank correlation coefficient. Partial correlation was also performed to control for potential confounders observed in the univariate analysis. Results Overall, 235 patients were included. Their mean age ranged between 14 and 45 years old and the body mass index (BMI) between 17 and 54. Women with mild hypercholesterolemia had a higher BMI and their fasting insulin was increased as well as indices of insulin resistance [Homeostatic model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI), Matsuda index] compared to women with PCOS with normal cholesterol levels. Correlation statistics suggested that the effect of serum lipids on the hormonal profile of patients was weak. Both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) exerted a significant mild negative correlation to glucose and insulin. However, after controlling the results for BMI and age (the two variables that were found significantly different in the univariate analysis) we observed that this effect was non-significant. Conclusion Mild hypercholesterolemia does not affect the hormonal profile of patients with PCOS; hence, to date, there is no evidence to suggest its treatment for the correction of menstrual and hormonal abnormalities in PCOS women.

Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity

2020 ◽  
Vol 502 ◽  
pp. 214-221 ◽  
Author(s):  
Xin Zeng ◽  
Yuan-jie Xie ◽  
Ya-ting Liu ◽  
Shuang-lian Long ◽  
Zhong-cheng Mo
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovarian Syndrome ◽  
Ovarian Syndrome

Metformin and N-acetyl Cysteine in Polycystic Ovarian Syndrome–-A Comparative Study

2010 ◽  
Vol 1 ◽  
pp. 117739361000100 ◽  
Author(s):  
Kar Gayatri ◽  
Jena Saubhagya Kumar ◽  
Behera Basanta Kumar
Keyword(s):  
Outcome Measures ◽  
Clinical Features ◽  
Polycystic Ovarian Syndrome ◽  
Secondary Outcome ◽  
Controlled Study ◽  
Chi Square ◽  
Hormonal Profile ◽  
Acetyl Cysteine ◽  
Randomised Controlled ◽  
Ovarian Syndrome

Objective To compare the effects of Metformin with N-acetyl cysteine in polycystic ovarian syndrome (PCOS). Methods A prospective, randomised controlled study was conducted in the Department of Obstetrics and Gynaecology in a Medical College and General Hospital. Total 115 cases of polycystic ovarian syndrome presenting with different complaints were selected for the study. Fifty nine cases were treated with Metformin (Group-M) and other 56 with N-acetyl cysteine (Group-N). Primary outcome measures are improvement in clinical features and biochemical profile, where as secondary outcome measures are improvement in hormonal profile and ultrasonographic findings. Statistical analysis was done by Z test and Chi square test. Results From each group, 50 patients were ultimately evaluated. There was significant improvement in some of the clinical features like weight gain, acne and hirsutism in group-N ( P < 0.05), but there was no significant change in other features like oligomenorrhea, amenorrhoea and infertility. The biochemical markers of insulin resistance like fasting insulin, fasting glucose/insulin ratio and HOMA-IR were significantly reduced in group-N. Hormone levels like serum LH, FSH, TT and LH/FSH ratio was significantly decreased in group-N, but FT, FT/TT ratio and SHBG were similar in both the groups. Ultrasonographic findings were similar in both the groups. Conclusion N-acetyl Cysteine had better improvement in clinical, biochemical and hormonal profile than Metformin in PCOS patients. It can be used as a substitute for insulin reducing medications in treatment of PCOS patients, considering its limited adverse effects.

scholarly journals Role of insulin sensitising agents in altering PSA level in PCOS

2017 ◽  
Vol 6 (11) ◽  
pp. 4986 ◽  
Author(s):  
Rajashree Panigrahy ◽  
Bratati Singh ◽  
Tapan K. Pattnaik ◽  
Sanjukta Misra
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovarian Syndrome ◽  
Specific Antigen ◽  
Serum Testosterone ◽  
Healthy Controls ◽  
Androgen Excess ◽  
Control Serum ◽  
Ovarian Syndrome ◽  
Significant Concentration

Background: Ovarian androgen production can be promoted by insulin resistance which leads to reproductive abnormalities in Polycystic Ovarian Syndrome (PCOS). A wide variety of female tissues can synthesize and secrete Prostate Specific Antigen (PSA). Androgens may take part a significant role in PSA secretion in PCOS. As insulin resistance stimulates androgen production, the baseline value of PSA may decline by insulin sensitising agents in PCOS. Present study is an attempt to measure the function of PSA as a marker of androgen excess in PCOS and to assess the role of insulin sensitising agent metformin in altering PSA level in PCOS.Methods: The study was undertaken to assess the insulin resistance, testosterone and PSA level in 45 women diagnosed as PCOS and 45 healthy controls. Alteration of insulin resistance, serum testosterone and PSA levels by metformin was also analysed.Results: A significant increase in testosterone, PSA level and insulin resistance was observed in PCOS cases when compared with control (p<0.001). When metformin was given for 4 months, improvement in insulin resistance and testosterone level was found in cases, but PSA values observed no change. Correlation was not found linking insulin resistance with PSA level prior to and after therapy.Conclusions: Serum PSA level could be detected in high significant concentration in PCOS women. Various researches explain that insulin resistance and BMI may perhaps control serum PSA level, but our result demonstrate no effect of insulin sensitising agent on serum PSA value.

Sign in / Sign up

Export Citation Format

Share Document